Randomized, Double-blind, Placebo-controlled Trial of Monosialoganglioside (GM1) Preventing Cisplatin-induced Neurotoxicity in NSCLC
Non-small Cell Lung Cancer
Enrolment: 300 · Results not recorded
Loading the evidence…
Drug
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Non-small Cell Lung Cancer
Enrolment: 300 · Results not recorded
Early Breast Cancer
Enrolment: 159 · Results not recorded
Neurotoxicity
Enrolment: 106 · Results not recorded
Multiple Myeloma
Enrolment: 100 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Acute spinal cord injury
Spinal cord injury lowered locomotor scores, raised malondialdehyde and caspase-3 and lowered superoxide dismutase and NGF. GM1 treatment reduced malondialdehyde, increased superoxide dismutase activity, downregulated caspase-3 mRNA and protein and upregulated NGF mRNA and protein, with significant…
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.